Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
As Bluebird’s CAR-T Competition Intensifies, Sickle Cell Therapy Brings Upside
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.
UniQure Aiming To Be First With Hemophilia B Gene Therapy
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
Astellas To Pay $3bn For Gene Therapy Company Audentes
Japanese company joins the ranks of big pharma buying up gene therapy pioneers
Vascepa Gains European Filing Nod
On the cusp of US approval, Amarin must wait until late 2020 for EMA judgement
Faron Lifted By US Immunotherapy Trial Approval
After a major setback to its lead asset last year, Faron looks to novel immunotherapy
'Serial Killer’ CAR-T Could Help Autolus Bounce Back
Data presentations at next week’s ASH meeting will be vital for Autolus to restore confidence in pipeline.